Biogen Idec And Swedish Orphan Biovitrum Present Data On Long-Lasting Hemophilia B Therapy At The World Federation Of Hemophilia Congress

Links shared publicly online about this topic.

  • 982
    total visits

Biogen Idec And Swedish Orphan Biovitrum Present Data On Long-Lasting Hemophilia B Therapy At The World Federation Of Hemophilia Congress

medicalnewstoday.com —

Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (STO: SOBI) announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-last

View full resource at medicalnewstoday.com

Tags: Hemophilia, Biogen Idec

  • Share

Most Recently Shared on July 31, 2010 at 2:05 pm By:

mnt_blood MNT Blood

Biogen Idec And Swedish Orphan Biovitrum Present Data On Long-Lasting Hemophilia B Therapy At The World Federation Of ... http://mnt.to/3GPn

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

medical_tweets medical_tweets

MNT Pharma News MNT Pharma News

MNT Clinical Trials MNT Clinical Trials

Advertisement